Sugi Predict

Sugi Predict / Compounds / SCHEMBL2648712

SCHEMBL2648712

SCHEMBL2648712

Nc1ccc(CC(=O)O)cn1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GABRP O00591 3/20 1.00
▸ GABRD O14764 3/20 1.00
▸ GABRA1 P14867 3/20 1.00
▸ GABRB1 P18505 3/20 1.00
▸ GABRG2 P18507 3/20 1.00
▸ GABRB3 P28472 3/20 1.00
▸ GABRA5 P31644 3/20 1.00
▸ GABRA3 P34903 3/20 1.00
▸ GABRA2 P47869 3/20 1.00
▸ GABRB2 P47870 3/20 1.00
▸ GABRA4 P48169 3/20 1.00
▸ GABRE P78334 3/20 1.00
▸ GABRA6 Q16445 3/20 1.00
▸ GABRG1 Q8N1C3 3/20 1.00
▸ GABRG3 Q99928 3/20 1.00
▸ GABRQ Q9UN88 3/20 1.00
▸ P4HTM Q9NXG6 1/20 0.61
▸ CPB2 Q96IY4 6/20 0.53
▸ NAPRT Q6XQN6 1/20 0.48
▸ NNMT P40261 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1712322 0.98 GABRP (0.96) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL18291273 0.84 GABRP (0.72) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL13727865 0.82 GABRP (0.70) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL2518100 0.81 GABRP (0.68) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL30462550 0.81 GABRP (0.68) GABRPGABRDGABRA1GABRB1GABRG2
Hydrochloric Acid SCHEMBL2275423 0.80 GABRP (0.67) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL14893668 0.79 GABRP (0.66) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL18291530 0.78 GABRP (0.64) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL18291366 0.78 GABRP (0.64) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL1712108 0.78 GABRP (0.64) GABRPGABRDGABRA1GABRB1GABRG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4563146-A1 FLAVIVIRUS INHIBITORS IRBM S.P.A. (IT) 2025-06-04 — — EP disclosed
US-11485745-B2 Amido spirocyclic amide and sulfonamide derivatives VALO HEALTH, INC. (US) 2022-11-01 — — US disclosed
US-20210171545-A1 AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES VALO HEALTH, INC. 2021-06-10 — — US disclosed
US-20210171545-A1 AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES VALO HEALTH, INC. 2021-06-10 — — US disclosed
CN-104520290-B Amido spirocyclic amide and sulfonamide derivatives 基因科技股份有限公司 2020-10-09 — — CN disclosed
US-10730889-B2 Amido spirocyclic amide and sulfonamide derivatives FORMA TM, LLC (US) 2020-08-04 — — US disclosed
US-10730889-B2 Amido spirocyclic amide and sulfonamide derivatives FORMA TM, LLC (US) 2020-08-04 — — US disclosed
US-20180339998-A1 AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES Valo Health, LLC 2018-11-29 — — US disclosed
EP-3087077-B1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL MERCK SHARP & DOHME (US) 2018-10-31 — — EP disclosed
US-9839629-B2 Inhibitors of the renal outer medullary potassium channel MERCK SHARP & DOHME CORP. (US) 2017-12-12 — — US disclosed
WO-2010029461-A1 HETEROARYLS AMIDE DERIVATIVES AND THEIR USE AS GLUCOKINASE ACTIVATORS PFIZER INC. (US) 2010-03-18 — — WO disclosed
US-20100063063-A1 Substituted Heteroaryls PFIZER INC 2010-03-11 — — US disclosed
WO-2009085185-A1 FUSED PYRIDINE, PYRIMIDINE AND TRIAZINE COMPOUNDS AS CELL CYCLE INHIBITORS AMGEN INC. (US) 2009-07-09 — — WO disclosed
EP-1169312-B1 GLUCOKINASE ACTIVATORS HOFFMANN LA ROCHE (CH) 2004-10-06 — — EP disclosed
CN-1151140-C Glucokinase activators - 2004-05-26 — — CN disclosed
CN-1349519-A Glucokinase activators HOFFMANN LA ROCHE (CH) 2002-05-15 — — CN disclosed
US-6320050-B1 2-SUBSTITUTED PHENYL-3-CYCLOALKYL SUBSTITUTED N-HETEROAROMATIC PROPIONAMIDES; USED TO INCREASE INSULIN SECRETION IN THE TREATMENT OF TYPE II DIABETES. HOFFMANN-LA ROCHE INC. 2001-11-20 — — US disclosed
US-20010039344-A1 Heteroaromatic glucokinase activators HOFFMANN-LA ROCHE INC. 2001-11-08 — — US disclosed
CN-1198746-A Tricyclic benzazepine * vasopressin antagonists AMERICAN CYANAMID CO (US) 1998-11-11 — — CN disclosed
WO-1995033724-A1 PHENETHANOLAMINE DERIVATIVES AND THEIR USE AS ATYPICAL BETA-ADRENOCEPTOR AGONISTS GLAXO GROUP LIMITED (GB) 1995-12-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210171545-A1 AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES STS, AADAC, SULT2A1 GABRP 784/4885GABRD 1144/4885GABRA1 907/4885
US-11485745-B2 Amido spirocyclic amide and sulfonamide derivatives STS, AADAC, SULT2A1 GABRP 784/4885GABRD 1144/4885GABRA1 907/4885
US-20180339998-A1 AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES STS, AADAC, SULT2A1 GABRP 784/4885GABRD 1144/4885GABRA1 907/4885
US-20010039344-A1 Heteroaromatic glucokinase activators GCKR, GCK, PDXK GABRP 626/4885GABRD 696/4885GABRA1 1837/4885
US-10730889-B2 Amido spirocyclic amide and sulfonamide derivatives STS, AADAC, SULT2A1 GABRP 784/4885GABRD 1144/4885GABRA1 907/4885
US-20100063063-A1 Substituted Heteroaryls GCKR, GCK, GALK1 GABRP 3291/4885GABRD 2882/4885GABRA1 2510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.